Shihan Chen

Ms. Shihan Chen


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2026 in Cells
Verified
Journal Article
Open access
PDF file
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
SCShihan Chen
Shihan Chen
EHElizabeth Hsueh
Elizabeth Hsueh
ISIsabella Scott
Isabella Scott
FXFeng Xue
Feng Xue
Neurodegenerative diseases like Alzheimer’s disease (AD) and Parkinson’s disease (PD) are regarded as systemic illnesses, mainly characterized by long-term neuroinflammation, metabolic dysregulation and barrier dysfunction. All these factors interact through the gut–immune–brain axis. The Mediterranean diet, rich in plant-based foods, olive oil, and fish, has been consistently associated with slower cognitive decline and reduced risk of neurodegeneration in observational studies and some clinical trials. This review provides a systems-level synthesis that distinguishes itself from previous narratives by integrating disease-specific mechanistic frameworks with multi-omics-guided precision nutrition strategies. We summarize recent evidence showing that this dietary pattern can remodel gut microbiota composition and enhance the production of bioactive metabolites such as short-chain fatty acids (SCFAs). These metabolites are associated with improved intestinal barrier integrity, reduced systemic inflammation, and potential modulation of brain functions. Within the central nervous system, diet-related metabolites have been linked to reduced neuroinflammation via modulation of microglial and astrocytic states. They have been linked to protection of mitochondrial function, maintenance of proteostasis, and preservation of blood–brain barrier (BBB) integrity. In AD and PD patients, adherence to this diet is associated with favorable changes in pathological hallmarks, including amyloid-beta (Aβ), tau, and α-synuclein accumulation. Nowadays, multi-omics tools, including single-cell transcriptomics, spatial transcriptomics and microbiome analysis, are widely used in this field, which helps researchers explore these complicated effects more deeply. Importantly, individual responses to the diet vary considerably due to differences in genetic background, gut microbial composition, and metabolic phenotypes, which underscore the need to move from generalized dietary guidelines toward personalized precision nutrition. The Mediterranean diet is not only a dietary pattern but also an effective way to modulate neuro-immune and metabolic networks. However, current evidence remains largely observational, and we critically discuss the need for more randomized controlled trials (RCTs) and standardized multi-omics data analysis frameworks. To sum up, the Mediterranean diet plays a neuroprotective role via the gut–immune–brain axis, and multi-omics techniques promote the development of precision nutrition. More trials and improved multi-omics systems are required to apply these research results in clinical practice.

27 October 2026 in Life
Verified
Journal Article
Open access
PDF file
JZJiahui Zhou
Jiahui Zhou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
JDJiaxing D ou
Jiaxing D ou
SCShihan Chen
Shihan Chen
FXFeng Xue
Feng Xue
Neurodegenerative diseases (NDs) have traditionally been regarded as brain-centered disorders driven primarily by the accumulation of pathological proteins. However, increasing evidence indicates that systemic metabolic dysfunction, chronic inflammation, intestinal dysbiosis, hepatic abnormalities, and barrier impairment may substantially influence disease susceptibility and progression. This review integrates current evidence on the gut–liver–brain axis (GLBA) and proposes Systemic Metabolic–Immune Reprogramming (SMIR) as a systems-level framework for understanding how peripheral disturbances may be translated into central nervous system vulnerability. Within this model, the gut generates microbial and metabolic signals, the liver functions as a metabolic–immune integrator that senses, transforms, buffers, or amplifies these signals, and the brain represents a downstream vulnerable organ in which persistent systemic disturbances reshape neuroimmune states and neuronal homeostasis. Particular emphasis is placed on the sequential and bidirectional interactions among intestinal barrier dysfunction, hepatic metabolic–immune activation, systemic inflammatory remodeling, blood–brain barrier vulnerability, and central neuroimmune dysregulation. Key molecular mediators include short-chain fatty acids, bile acids, tryptophan–kynurenine metabolites, trimethylamine N-oxide, ceramides, hepatokines, complement components, extracellular vesicles, and inflammatory cytokines, together with signaling pathways involving TLRs, FXR/TGR5, NLRP3, mitochondrial stress, and cGAS–STING. We further discuss how microglial and astrocytic metabolic reprogramming, mitochondrial dysfunction, ferroptosis, and impaired proteostasis may connect systemic metabolic stress with neuronal injury. Disease-specific manifestations of this framework are examined in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple system atrophy, highlighting both shared systemic mechanisms and distinct patterns of organ susceptibility. Emerging approaches, including longitudinal multi-omics, spatial transcriptomics, metabolomics, extracellular-vesicle profiling, organoid models, and artificial intelligence-assisted integration, may enable reconstruction of inter-organ communication networks and identification of disease-specific SMIR signatures. Therapeutically, this framework supports a shift from isolated downstream targets toward coordinated modulation of microbiome composition, hepatic metabolism, immune activity, barrier integrity, nutrition, and CNS pathology. Although causal relationships remain to be established, the GLBA–SMIR perspective provides a testable conceptual foundation for earlier diagnosis, patient stratification, precision nutrition, and multi-system intervention in neurodegenerative diseases.

Verified
Journal Article
Open access
PDF file
SCShihan Chen
Shihan Chen
XWXingyu Wang
Xingyu Wang
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
FXFeng Xue
Feng Xue
Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlation studies toward investigation of causal relationships in preclinical models. Human observational studies have reported associations between alterations in gut microbiota and the entire spectrum of AD, from the preclinical stage to dementia, and are associated with Amyloid-beta (Aβ) deposition, phosphorylated Tau (p-tau) positivity, dysregulation of bile acid and short-chain fatty acid (SCFA) metabolism, as well as impaired intestinal barrier function. The strongest causal evidence currently derives from germ-free or antibiotic-treated animal models, fecal microbiota transplantation (FMT) between healthy controls and AD patients, and colonization by specific bacterial strains or metabolites—interventions that have been shown to modulate Aβ load, tau phosphorylation, microglial activation, synaptic pruning, and cognitive behavior in animal models. Mechanistically, the gut–brain axis in AD has been proposed to integrate four interconnected pathways, with the strength of evidence and the extent of human validation varying considerably across them: (1) reduced production of SCFA-producing bacteria accompanied by upregulation of pro-inflammatory pathways; (2) disruption of intestinal epithelial tight junctions, allowing lipopolysaccharide (LPS) and bacterial toxins to enter the systemic circulation; (3) reprogramming of peripheral and central innate immune systems, leading to hyperactivation of microglia and complement-mediated synaptic clearance; and (4) global rearrangement of microbial metabolite networks (including SCFAs, bile acids, tryptophan metabolites, and LPS), has been proposed to collectively regulate Aβ homeostasis, tau pathology, microglial activation, and blood–brain barrier (BBB) integrity. Clinically, the evidence base remains uneven: probiotics have been associated with some improvements in some inflammatory markers and cognitive measures in small randomized controlled trials (RCTs); FMT has been reported in case studies in human AD; modified ketogenic diets have been associated with cerebrospinal fluid (CSF) biomarkers; and molecules such as GV-971 (Sodium Oligomannate) provide proof-of-concept for microbiota-targeted strategies, though independent validation is needed. Overall, gut microbiota research in AD has advanced considerably, with animal and human studies suggesting that dysbiosis may contribute to AD pathology through immune, metabolic, and barrier-related pathways, although clinical intervention evidence remains preliminary and requires further validation.

30 July 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
SCShihan Chen
Shihan Chen
XWXingyu Wang
Xingyu Wang
JDJiaxing D ou
Jiaxing D ou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
FXFeng Xue
Feng Xue
Research on gut microbiota in Alzheimer’s disease (AD) has progressed from observational correlations to the validation of causal relationships. Human studies consistently demonstrate that alterations in gut microbiota span the entire spectrum of AD, from the preclinical stage to dementia, and are associated with Amyloid-beta (Aβ) deposition, phosphorylated Tau (p-tau) positivity, dysregulation of bile acid and short-chain fatty acid (SCFA) metabolism, as well as impaired intestinal barrier function. The strongest causal evidence comes from germ-free/antibiotic-treated animal models, fecal microbiota transplantation (FMT) between healthy controls and AD patients, and colonization by specific pathogenic bacteria or metabolites—interventions that directly modulate Aβ load, tau phosphorylation, microglial activation, synaptic pruning, and cognitive behavior. Mechanistically, the gut-brain axis in AD integrates four interconnected pathways: (1) reduced production of SCFA-producing acidogenic bacteria accompanied by upregulation of pro-inflammatory pathways; (2) disruption of intestinal epithelial tight junctions, allowing lipopolysaccharide (LPS) and bacterial toxins to enter the systemic circulation; (3) reprogramming of peripheral and central innate immune systems, leading to hyperactivation of microglia and complement-mediated synaptic clearance; and (4) global rearrangement of microbial metabolite networks (including SCFAs, bile acids, tryptophan-ketouric acid derivatives, and LPS), collectively regulating Aβ homeostasis, tau pathology, microglial activation, and blood-brain barrier (BBB) integrity. Clinically, evidence levels remain uneven: probiotics/bifidobiotics have demonstrated improvements in inflammation and certain cognitive domains in small randomized controlled trials (RCTs); FMT has only been supported by case reports in human AD; modified ketogenic diets have shown correlations with cerebrospinal fluid (CSF) biomarkers; molecules such as GV-971 provide proof-of-concept for microbiota-targeted strategies but require broader independent validation. Overall, gut microbiota research in AD has entered a new phase, with animal and human studies indicating that dysbiosis can drive AD pathology through multiple pathways including immune, metabolic, and barrier dysfunction, though clinical intervention evidence remains inconsistent and requires further validation.

8 October 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JZJiahui Zhou
Jiahui Zhou
JWJiahui Wang
Jiahui Wang
LPLi xiao Pu
Li xiao Pu
JDJiaxing D ou
Jiaxing D ou
SCShihan Chen
Shihan Chen
FXFeng Xue
Feng Xue
Neurodegenerative diseases (NDs) have traditionally been regarded as brain-centered disorders driven primarily by the accumulation of pathological proteins. However, increasing evidence indicates that systemic metabolic dysfunction, chronic inflammation, intestinal dysbiosis, hepatic abnormalities, and barrier impairment may substantially influence disease susceptibility and progression. This review integrates current evidence on the gut–liver–brain axis (GLBA) and proposes Systemic Metabolic–Immune Reprogramming (SMIR) as a systems-level framework for understanding how peripheral disturbances may be translated into central nervous system vulnerability. Within this model, the gut generates microbial and metabolic signals, the liver functions as a metabolic–immune integrator that senses, transforms, buffers, or amplifies these signals, and the brain represents a downstream vulnerable organ in which persistent systemic disturbances reshape neuroimmune states and neuronal homeostasis. Particular emphasis is placed on the sequential and bidirectional interactions among intestinal barrier dysfunction, hepatic metabolic–immune activation, systemic inflammatory remodeling, blood–brain barrier vulnerability, and central neuroimmune dysregulation. Key molecular mediators include short-chain fatty acids, bile acids, tryptophan–kynurenine metabolites, trimethylamine N-oxide, ceramides, hepatokines, complement components, extracellular vesicles, and inflammatory cytokines, together with signaling pathways involving TLRs, FXR/TGR5, NLRP3, mitochondrial stress, and cGAS–STING. We further discuss how microglial and astrocytic metabolic reprogramming, mitochondrial dysfunction, ferroptosis, and impaired proteostasis may connect systemic metabolic stress with neuronal injury. Disease-specific manifestations of this framework are examined in Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, Huntington’s disease, and multiple system atrophy, highlighting both shared systemic mechanisms and distinct patterns of organ susceptibility. Emerging approaches, including longitudinal multi-omics, spatial transcriptomics, metabolomics, extracellular-vesicle profiling, organoid models, and artificial intelligence-assisted integration, may enable reconstruction of inter-organ communication networks and identification of disease-specific SMIR signatures. Therapeutically, this framework supports a shift from isolated downstream targets toward coordinated modulation of microbiome composition, hepatic metabolism, immune activity, barrier integrity, nutrition, and CNS pathology. Although causal relationships remain to be established, the GLBA–SMIR perspective provides a testable conceptual foundation for earlier diagnosis, patient stratification, precision nutrition, and multi-system intervention in neurodegenerative diseases.

13 November 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
JWJiahui Wang
Jiahui Wang
PDPengcheng Duan
Pengcheng Duan
JDJiaxing D ou
Jiaxing D ou
SCShihan Chen
Shihan Chen
FXFeng Xue
Feng Xue
Alzheimer’s disease (AD) is no longer viewed simply as a proteinopathy driven by amyloid-β (Aβ) and tau. It also involves neuroimmune dysregulation, blood-brain barrier (BBB) and neurovascular unit (NVU) dysfunction, gut-brain axis perturbation, and peripheral metabolic imbalance. Dietary lipids are biologically distinct molecules that can influence these systems through membrane remodeling, lipid-mediator generation, receptor signaling, metabolic support, and central-peripheral crosstalk. Clinical studies of n-3 polyunsaturated fatty acids (PUFAs) and related lipid interventions have nevertheless produced inconsistent or negative results, which may reflect both genuinely limited efficacy in some settings and heterogeneity in lipid species, disease stage, formulation, exposure, and host background. We therefore place the proposed 4D framework within a broader systems-physiology concept of allostatic integrity: the capacity of interacting neural, glial, vascular, immune, and metabolic systems to adapt to repeated perturbations and return toward functional stability. We further use “biological memory” as an operational concept for persistent molecular and cellular state changes—such as epigenetic, metabolic, lipidomic, and glial-state remodeling—that can alter responses to subsequent challenges. The 4D framework comprises Disease stage, Dominant driver pathway, Delivery and formulation, and Data-guided stratification. It is intended as a hypothesis-generating research framework for trial design and stratification, not as a validated clinical algorithm. The 4D framework has not yet been prospectively validated, and its prospective utility remains to be tested.